Skip to Content

Sivextro Approval History

Sivextro (tedizolid phosphate) is an oxazolidinone antibiotic drug indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI).

Development History and FDA Approval Process for Sivextro

Jun 20, 2014Approval FDA Approves Sivextro (tedizolid phosphate) to Treat Skin Infections
Jun  6, 2014Cubist Announces Publication of Pivotal Data from Sivextro (tedizolid phosphate) ESTABLISH-2 Trial
Mar 31, 2014FDA Advisory Committee Unanimously Recommends Approval of Sivextro (tedizolid phosphate)
Dec 30, 2013Cubist Announces FDA Acceptance of Tedizolid New Drug Application with Priority Review
Oct 23, 2013Cubist Announces Submission of New Drug Application for Investigational Antibiotic Tedizolid for Treatment of Serious Skin Infections

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.